PA
NRIX icon

Profund Advisors’s Nurix Therapeutics NRIX Stock Holding History

Profund Advisors’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.04M Buy
66,993
+32,413
+94% +$537K 0.04% 335
2025
Q4 		$656K Buy
34,580
+14,125
+69% +$203K 0.02% 467
2025
Q3 		$189K Buy
20,455
+4,022
+24% +$41.8K 0.01% 995
2025
Q2 		$187K Sell
16,433
-6,754
-29% -$73K 0.01% 921
2025
Q1 		$275K Buy
23,187
+283
+1% +$4.73K 0.01% 722
2024
Q4 		$432K Buy
22,904
+3,866
+20% +$88.6K 0.02% 588
2024
Q3 		$428K Sell
19,038
-6,550
-26% -$148K 0.02% 597
2024
Q2 		$534K Sell
25,588
-7,472
-23% -$116K 0.02% 481
2024
Q1 		$486K Buy
+33,060
New +$356K 0.02% 586
2023
Q4 		– Sell
-17,233
Closed -$135K – 1147
2023
Q3 		$135K Sell
17,233
-4,016
-19% -$36.7K 0.01% 922
2023
Q2 		$212K Sell
21,249
-5,110
-19% -$52.1K 0.01% 941
2023
Q1 		$234K Buy
+26,359
New +$275K 0.01% 885

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Profund Advisors's NRIX Position: Q1 2026 in Review

Profund Advisors increased its Nurix Therapeutics (NRIX) stake by 94% in Q1 2026, buying an estimated $537K and bringing the position to 66,993 shares worth $1.04M. The position accounts for 0.04% of the portfolio, ranked #335.

Profund Advisors first reported a position in NRIX in Q1 2023 and has held it in 12 quarters since. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Profund Advisors held 66,993 shares of Nurix Therapeutics worth $1.04M as of Q1 2026.
  • Profund Advisors bought 32,413 Nurix Therapeutics shares in Q1 2026, an estimated $537K.
  • Nurix Therapeutics made up 0.04% of Profund Advisors's portfolio in Q1 2026, its #335 holding.
  • Profund Advisors first reported a position in Nurix Therapeutics in Q1 2023 and has held it in 12 quarters since.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Profund Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.